Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Fergus J Couch, Hermela Shimelis, Chunling Hu...
https://pubmed.ncbi.nlm.nih.gov/28418444/Actively Recruiting
Led by Peking University Third Hospital · Updated on 2026-04-15
480
Participants Needed
1
Research Sites
469 weeks
Total Duration
Researchers are studying women who have a moderate-to-high genetic risk for hereditary ovarian cancer to understand how different preventive surgical options work and how safe they are. They aim to compare individualized preventive surgeries, like removing fallopian tubes now and delaying ovary removal, against standard care or close monitoring to see which best reduces ovarian cancer risk. The study also looks at how these surgeries affect ovarian function and quality of life. The study follows women who carry specific gene mutations such as BRCA1, BRCA2, RAD51C, and others. Participants choose one of three paths with their doctors standard risk-reducing surgery removing both fallopian tubes and ovaries at once RRSO, removing fallopian tubes first and delaying ovary removal RS-DO, or close monitoring with ultrasound and blood tests if they decline surgery. The study includes both past data from 2020 onward and new participants, with follow-up planned for at least 3 years. Participants will have their clinical data collected, including surgical pathology reviewed centrally to detect early signs of cancer. They will complete quality of life and psychological assessments over time. Researchers will track ovarian, fallopian tube, and peritoneal cancer incidence as the main outcome over up to 15 years. Safety, quality of life, menopausal symptoms, and psychological distress are also monitored. The study uses strict data validation and regular audits to ensure accuracy.
CONDITIONS
A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer
A
Associate Chief Physician/Associate Consultant, Doctor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Peking University Third Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo prophylactic surgery based on their assigned group: concurrent bilateral salpingo-oophorectomy (RRSO), salpingectomy with delayed oophorectomy (RS-DO), or decline surgery and start close monitoring.
1 surgical visit
Duration - Up to 1 year
Participants who had surgery receive follow-up care including pathology review for occult cancer and assessments of menopausal symptoms and quality of life.
Visits at baseline, 1 month, 6 months, and 1 year post-surgery or enrollment
Duration - Up to 15 years
Participants are followed for up to 15 years to monitor for the incidence of ovarian cancer and breast cancer, with regular assessments for those in the close monitoring group involving ultrasound and biomarker testing.
Regular monitoring visits every 6 to 12 months depending on group assignment
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Fergus J Couch, Hermela Shimelis, Chunling Hu...
https://pubmed.ncbi.nlm.nih.gov/28418444/Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes...
https://pubmed.ncbi.nlm.nih.gov/28632866/Mary B Daly, Tuya Pal, Michael P Berry...
https://pubmed.ncbi.nlm.nih.gov/33406487/Hyuna Sung, Jacques Ferlay, Rebecca L Siegel...
https://pubmed.ncbi.nlm.nih.gov/33538338/Tuya Pal, Jenny Permuth-Wey, Judith A Betts...
https://pubmed.ncbi.nlm.nih.gov/16284991/Robert J Kurman, Ie-Ming Shih
https://pubmed.ncbi.nlm.nih.gov/20154587/Wanqing Chen, Rongshou Zheng, Peter D Baade...
https://pubmed.ncbi.nlm.nih.gov/26808342/Miranda P Steenbeek, Marline G Harmsen, Nicoline Hoogerbrugge...
https://pubmed.ncbi.nlm.nih.gov/34081085/Alexandra Lukey, A Fuchsia Howard, Alice J Mei...
https://pubmed.ncbi.nlm.nih.gov/40481395/Miranda P Steenbeek, Majke H D van Bommel, Joanna intHout...
https://pubmed.ncbi.nlm.nih.gov/37045546/Peking University Third Hospital
Lead Sponsor